Nicotinamide phosphoribosyltransferase inhibitors, design, preparation and SAR.

Christensen, Mette Knak; Erichsen, Kamille Dumong; Olesen, Uffe Hogh; Tjørnelund, Jette; Fristrup, Peter; Thougaard, Annemette; Nielsen, Søren Jensby; Sehested, Maxwell; Jensen, Peter B.; Loza, Einars; Kalvinsh, Ivars; Garten, Antje; Kiess, Wieland; Bjorkling, Fredrik

Published in:
Open Journal of Medicinal Chemistry

Link to article, DOI:
10.1021/jm4009949

Publication date:
2013

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation and SAR.

Mette Knak Christensen, Kamille Dumong Erichsen, Uffe Høgh Olesen, Jette Tjørnelund, Peter Fristrup, Annemette Thougaard, Søren Jensby Nielsen, Maxwell Sehested, Peter Buhl Jensen, Einar Loza, Ivars Kalvinsh, Antje Garten, Wieland Kiess, and Fredrik Bjorkling

J. Med. Chem., Just Accepted Manuscript • Publication Date (Web): 28 Oct 2013
Downloaded from http://pubs.acs.org on November 12, 2013
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation and SAR.

Mette K. Christensen,† Kamille D. Erichsen,† Uffe H. Olesen,†,§ Jette Tjørnelund,† Peter Fristrup,∗ Annemette Thougaard,† Søren Jensby Nielsen,† Maxwell Sehested,†,§ Peter B. Jensen,†

Einars Loza,ψ Ivars Kalvinsh,ψ Antje Garten,‡ Wieland Kiess,‡ and Fredrik Björkling,†‡,*

†Topotarget A/S, Symbion, Fruebjergvej 3, DK-2100 Copenhagen, Denmark
‡Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark
§Experimental Pathology Unit, National University Hospital, Biocentre, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark
‡Center for Pediatric Research, Hospital for Children and Adolescents, University of Leipzig, Liebigstr. 21, 04301 Leipzig, Germany

Department of Chemistry, Technical University of Denmark, Kemitorvet 207, DK-2800 Lyngby, Denmark
ψLatvian Institute of Organic Synthesis, Aizkraukles 21, LV-1006 Riga, Latvia

KEYWORDS: Cancer, medicinal chemistry, nicotinamide phosphoribosyltransferase, NAMPT, nicotinamide adenine dinucleotide (NAD), mouse xenograft.
Abstract.

Existing pharmacological inhibitors for nicotinamide phosphoribosyltransferase (NAMPT) are promising therapeutics for treating cancer. Using medicinal and computational chemistry methods, the structure-activity relationship for novel classes of NAMPT inhibitors is described and compounds optimized. Compounds are designed inspired by the NAMPT inhibitor APO866 and cyanoguanidine inhibitor scaffolds. In comparison with recently published derivatives the new analogues exhibit an equally potent anti-proliferative activity in vitro and comparable activity in vivo. The best performing compounds from these series showed sub-nanomolar anti-proliferative activity towards a series of cancer cell-lines (compound 15: IC\textsubscript{50} 0.025 nM and 0.33 nM, in A2780 (ovarian carcinoma) and MCF-7 (breast), respectively), and potent anti-tumour in vivo activity in well tolerated doses in a xenograft model. In an A2780 xenograft mouse model with large tumours (500 mm\textsuperscript{3}) compound 15 reduced the tumour volume to one fifth of the starting volume at a dose of 3 mg/kg administered i.p., bid, day 1-9. Thus, compounds found in this study compared favourably with compounds already in the clinic and warrant further investigation as promising lead molecules for the inhibition of NAMPT.

Introduction

Inhibition of nicotinamide adenine dinucleotide, (NAD) production has recently been suggested as a principle for inducing death of cells with high demand for this dinucleotide.\textsuperscript{1} This is particularly true for cancer cells due to increased metabolism and high activity of NAD consuming enzymes. NAD is an essential cofactor in redox reactions and as such involved in cellular energy production and metabolism without being substantially consumed. However, besides being a cofactor, NAD serves as the substrate for mono-ADP-ribosyltransferases,\textsuperscript{2} poly-ADP-ribose polymerases (PARPs),\textsuperscript{3} and sirtuins,\textsuperscript{4} all of these converting NAD to nicotinamide. Also, NAD is consumed as the precursor for a number of Ca\textsuperscript{2+} - releasing second messengers (e.g., cADPR, NAADP).\textsuperscript{5,6}
Thus, the increased dependence on glycolysis and elevated expression or activity of PARPs,\textsuperscript{7-9} and sirtuins,\textsuperscript{4} characteristic for malignant cells, make these more sensitive to NAD availability as compared with normal cells.\textsuperscript{10,11}

In the organism several pathways for the synthesis of NAD are known. Besides the "de novo" pathway using tryptophan as precursor, NAD can alternatively be synthesized or resynthesized from nicotinamide, a sequence where Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the rate limiting step.\textsuperscript{12-14} Thus, inhibition of NAMPT enzyme activity causes a direct inhibition of NAD production. Importantly, normal cells can use an alternative pathway for NAD synthesis from nicotinic acid (NA), catalyzed by nicotinic acid phosphoribosyltransferase (NAPRT).\textsuperscript{15-17} Unlike most normal tissues many cancer cell lines, and primary tumours, are deficient in NAPRT activity.\textsuperscript{18} Furthermore, an increased concentration of NAMPT in colorectal, ovarian, and prostate cancer cells has been reported.\textsuperscript{10,19,20} Altogether, inhibition of NAD production via NAMPT inhibition is suggested to be a valid principle for selective inhibition of cancer cell growth and as such represents an attractive target for drug discovery.

A few classes of NAMPT inhibitors have been reported such as compounds APO866 (1)\textsuperscript{21} and CHS828, (2)\textsuperscript{22} which have entered the clinic, and more recent structures like TRON-8\textsuperscript{23} and CB30865\textsuperscript{24} for which biological data have been reported (Figure 1). Biological data for NAMPT inhibitor MCP-8640 is also reported but no chemical structure.\textsuperscript{25} These NAMPT inhibitors show potent anti-proliferative activity in a spectrum of cancer cell lines and in vivo efficacy in both solid tumours and leukemia in preclinical studies.\textsuperscript{26,27} A comprehensive literature review on NAMPT inhibitors including patents was recently published.\textsuperscript{28} Originally, 1 was developed as an inhibitor of NAMPT and displays anti-proliferative activities comparable to compound 2 for which the molecular target was unknown until recently.\textsuperscript{29-31} Safety, pharmacokinetics and biological effect of compound 1 and 2 (and a pro-drug thereof, 3, Figure 1) have been reported from five phase I clinical trials performed in patients with advanced disease.\textsuperscript{32-34} In these trials, not surprisingly in phase I, no objective response was found and for both compounds the
dose limiting toxicity was found to be thrombocytopenia. Compound 2 was tested in an oral formulation but was later transformed to a pro-drug, compound 3, to obtain improved pharmacokinetics.\textsuperscript{35,36} To obtain good exposure both compound 1 and 3 were administered i.v. using long term continued infusion.\textsuperscript{33,34} Both compounds have entered phase II clinical trials, however, results from these trials are not yet available.

**Figure 1.** NAMPT inhibitors. 1, APO866 (activity see Table 1); 2, CHS-828 (activity see Table 1); 3, EB 1627 (pro-drug of CHS828); TRON-8 (IC\textsubscript{50} (SH-SY5Y) 3.8 nM))\textsuperscript{23}; and CB30865 (IC\textsubscript{50} (W1L2) 2.8 nM)\textsuperscript{37}.

Inspired by these results and with the aim of finding compounds with improved toxicological and activity properties we here report the structure activity relationship (SAR) for a new series of NAMPT inhibitors based on structural modifications of compound 1 and 2. The results from the SAR study were rationalized and new compounds designed using computational chemistry methods.
Results and discussion

Chemistry

A series of 2-cyanoguanidines 11-25 was synthesized using a general strategy (Scheme 1, Table 1).

Treatment of dimethyl cyanocarbonimidodithioate (I) with 4-pyridylamine (IIa), 3-pyridylamine (IIb) or aniline (IIc) produced methyl N'-cyano-N-arylcarbamimidothioates IIIa-c, which were condensed with pre-assembled hydroxamate amines IVa-c or sulfonamide amines Va-k to give the corresponding 2-cyanoguanidines 11-25.

Scheme 1. Convergent Synthesis of 2-Cyanoguanidine Derivatives 11-25
Although this convergent approach was successful in most cases, a stepwise formation of the side chain was used for some 2-cyanoguanidine derivatives such as 4-10 (Scheme 2, Tables 1 and 2).

Thus, the condensation of methyl N'-cyano-N-(pyridin-4-yl)carbamimidothioate (IIIa) with 7-aminooctanoic acid (VIa) or optically active 2-methyl or 2-benzyl-7-aminoheptanoic acids VIb-e produced 7-guanidinoheptanoic acid derivatives VIIa-e. These intermediate acids VIIa-e afforded the target $N$-hydroxycarboxamides 4-10 when treated with hydroxylamines VIIIa-c in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) or $O$-(7-azabenzotriazol-1-yl)-$N,N',N'$-tetramethyluronium hexafluorophosphate (HATU).
Scheme 2. Synthesis of 2-Cyanoguanidine Derivatives 4-10 via Carboxylic Acid Intermediates

VIIa-e

<table>
<thead>
<tr>
<th>No</th>
<th>R</th>
<th>No</th>
<th>R&lt;sup&gt;3&lt;/sup&gt;</th>
<th>No</th>
<th>R</th>
<th>R&lt;sup&gt;3&lt;/sup&gt;</th>
<th>R&lt;sup&gt;4&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>VIa, VIIa</td>
<td>H</td>
<td>VIIIa</td>
<td>H</td>
<td>4</td>
<td>H</td>
<td>H</td>
<td></td>
</tr>
<tr>
<td>VIIb, VIIb</td>
<td>(R)-Me</td>
<td>VIIIb</td>
<td>Bn</td>
<td>5</td>
<td>H</td>
<td>Bn</td>
<td></td>
</tr>
<tr>
<td>VIIc, VIIc</td>
<td>(S)-Me</td>
<td>VIIIc</td>
<td></td>
<td>6</td>
<td>(S)-Me</td>
<td>H</td>
<td></td>
</tr>
<tr>
<td>VId, VIId</td>
<td>(R)-Bn</td>
<td></td>
<td></td>
<td>7</td>
<td>(R)-Me</td>
<td>H</td>
<td></td>
</tr>
<tr>
<td>Vle, VIIe</td>
<td>(S)-Bn</td>
<td></td>
<td></td>
<td>8</td>
<td>(S)-Bn</td>
<td>H</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>9</td>
<td>(R)-Bn</td>
<td>H</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10</td>
<td>H</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(for structures 4, 5 and 10 see Table 1, for 6-9 see Table 2)

A similar convergent approach to Scheme 1 was used for the preparation of a series of 1,2-diaminocyclobutene-3,4-diones 26-36 (Scheme 3, Table 3).<sup>39</sup> Reaction of 3,4-diethoxy-3-cyclobutene-1,2-dione (IX) with 4-pyridylamine (IIa) afforded intermediate amidoester X, which was treated with amines IV<sub>a,b,d</sub>, Va-e,j,l,m to obtain target 1,2-diaminocyclobutene-3,4-diones 26-36.
Scheme 3. Convergent Synthesis of 1,2-Diaminocyclobutene-3,4-dione derivatives 26-36

(for structures see Table 3)
$N,N'$-Disubstituted urea derivatives 37, 38, 40-50 (Table 4) were prepared by reacting of such carbonic acid derivatives as $N,N'$-carbonyldiimidazole (CDI) or 4-nitrophenyl chloroformate with 4-pyridylamine (IIa) or 3-picolylamine (IIId) followed by appropriate pre-assembled amines IVb, Va-f,k,n (Scheme 4).

**Scheme 4. Synthesis of $N,N'$-Disubstituted Urea Derivatives 37, 38, 40-50**

\[
\text{R}^1-\text{NH}_2 \xrightarrow{\text{CDI or } \rho\text{-nitrophenyl chloroformate}} \text{R}^1-\text{NH}_2 - \text{X} \quad \text{IVb, Va-f,k,n} \quad \text{37, 38, 40-50}
\]

(For structures see Table 4)

<table>
<thead>
<tr>
<th>No</th>
<th>R$^1$</th>
<th>R$^2$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ve, 37</td>
<td>4-Py</td>
<td><img src="image" alt="Structure Ve, 37" /></td>
</tr>
<tr>
<td>IVb, 38</td>
<td>3-Pic</td>
<td><img src="image" alt="Structure IVb, 38" /></td>
</tr>
<tr>
<td>Vm, 40</td>
<td>4-Py</td>
<td><img src="image" alt="Structure Vm, 40" /></td>
</tr>
<tr>
<td>Vm, 41</td>
<td>3-Pic</td>
<td><img src="image" alt="Structure Vm, 41" /></td>
</tr>
<tr>
<td>Va, 42</td>
<td>4-Py</td>
<td><img src="image" alt="Structure Va, 42" /></td>
</tr>
<tr>
<td>Vo, 43</td>
<td>4-Pic</td>
<td><img src="image" alt="Structure Vo, 43" /></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No</th>
<th>R$^1$</th>
<th>R$^2$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vj, 45</td>
<td>3-Pic</td>
<td><img src="image" alt="Structure Vj, 45" /></td>
</tr>
<tr>
<td>Vd, 46</td>
<td>3-Pic</td>
<td><img src="image" alt="Structure Vd, 46" /></td>
</tr>
<tr>
<td>Ve, 47</td>
<td>3-Pic</td>
<td><img src="image" alt="Structure Ve, 47" /></td>
</tr>
<tr>
<td>Vf, 48</td>
<td>3-Pic</td>
<td><img src="image" alt="Structure Vf, 48" /></td>
</tr>
<tr>
<td>Vn, 49</td>
<td>3-Pic</td>
<td><img src="image" alt="Structure Vn, 49" /></td>
</tr>
</tbody>
</table>
The \(N,N'\)-disubstituted thiourea derivative 39 was synthesized by the condensation of 3-picolylamine II\(d\) with di(2-pyridyl) thionocarbonate (DPT) followed by treatment of \textit{in situ} formed intermediate isothiocyanate X\(IIb\) with amine IV\(b\). The \(N,N'\)-disubstituted thiourea derivative 51 was prepared from amine V\(d\) and isothiocyanate X\(IIa\), which in turn was obtained from 4-pyridilamine II\(a\) and carbon disulfide (Scheme 5, Table 4).

\textbf{Scheme 5. Synthesis of \(N,N'\)-Disubstituted Thiourea Derivatives 39 and 51}

\[
\begin{array}{cccc}
\text{R}^1-\text{NH}_2 & \overset{\text{CS}_2 \text{ or DPT}}{\rightarrow} & \text{R}^1-\text{NCS} & \overset{\text{R}^2-\text{NH}_2}{\rightarrow} \\
\text{II}a, \text{R}^1 = \text{4-pyridyl} & \text{XII}a, \text{R}^1 = \text{4-pyridyl} & \text{39, 51} \\
\text{II}d, \text{R}^1 = \text{3-picolyl} & \text{XII}b, \text{R}^1 = \text{3-picolyl} & \text{IV}b, \text{V}d \\
\text{No} & \text{R}^1 & \text{R}^2 \\
\text{IV}b, 39 & \text{3-Pic} & \text{V}d, 51 & \text{4-Py} \\
\end{array}
\]

The hydroxylamine intermediates VIII\(a,b,d,e\) of carboxamide amines IV and sulfonamide amines V were synthesized starting from 2-hydroxyisooindoline-1,3-dione which was alkylated with cyclohexyl alcohol XIII\(a\) upon \textit{Mitsunobu} conditions, with cyclohexylmethyl bromide XIII\(b\) in the presence of
K₂CO₃ in DMSO, or with 2-(4-morpholinyl)ethyl chloride (XIIIc) in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) to give the O-substituted derivatives XIVa-c. Removal of the phthalimide protective group of compounds XIVa-c gave O-hydroxylamine derivatives VIIIa, VIIId, and VIIIe, respectively. Compound VIIIa was further converted into N-monobenzyl derivative VIIIb via 2-nitrobenzosulfonamide intermediates XV and XVI (Scheme 6).

Scheme 6. Preparation of Hydroxylamines VIIIa,b,d,e

Another series of N,O-disubstituted hydroxylamines VIIIc,f-i were prepared from cyclic ketones XVIIa-c and O-(2-morpholinoethyl)hydroxylamine (VIIIe) or 3-morpholinopropan-1-amine (XVIII) by reductive amination (Scheme 7). Condensation of the ketones XVIIa-c with the amino compounds VIIIe or XVIII gave the corresponding intermediate oximes or imines XIXa-e, which were reduced to saturated structures VIIIc,f-i.
Scheme 7. Preparation of Hydroxylamines VIIIc,f,h and Amines VIIIg,i

<table>
<thead>
<tr>
<th>No</th>
<th>n</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr>
<td>XIXa, VIIIf</td>
<td>1</td>
<td>O</td>
</tr>
<tr>
<td>XIXb, VIIIg</td>
<td>1</td>
<td>CH₂</td>
</tr>
<tr>
<td>XIXc, VIIIh</td>
<td>2</td>
<td>O</td>
</tr>
<tr>
<td>XIXd, VIIIc</td>
<td>3</td>
<td>O</td>
</tr>
<tr>
<td>XIXe, VIIIi</td>
<td>3</td>
<td>CH₂</td>
</tr>
</tbody>
</table>

By a similar one-pot reductive amination protocol O-(2-morpholinoethyl)hydroxylamine (VIIIe) and benzaldehyde afforded N-benzyl-O-(2-morpholinoethyl)hydroxylamine (VIIIj) (Scheme 8).

Scheme 8. Synthesis of N-Benzyl-O-(2-morpholinoethyl)hydroxylamine (VIIIj)

The hydroxamate amines IVa-d were prepared from N-Boc protected ω-amino hexanoic, heptanoic, and octanoic acids XXa-c which were condensed with hydroxylamine VIIIj in the presence of EDC or with hydroxylamine VIIIc in the presence of HATU to afford the corresponding hydroxamates XXIa-d which were deprotected to obtain compounds IVa-d (Scheme 9).
Scheme 9. Synthesis of Hydroxamate Amines IVa-d

The synthesis of sulfonamide amines Va-n was based on the condensation of phthalyl-protected \( \omega \)-aminopentane, aminohexane, and aminooctane sulfonyl chlorides XXVa-c with appropriate amine or hydroxylamine derivatives to produce the corresponding sulfonamides XXVIa-j,l-n (Scheme 10). In the case of tertiary sulfonamides XXVIh,i,l,m the synthesis included an extra alkylation step of initially obtained secondary sulfonamides XXVIIa-c. The following treatment of the sulfonamides XXVIa-j,l-n and XXVIIc with hydrazine produced the sulfonamide amines Va-n. The intermediate sulfonyl chlorides XXVa,b were obtained by a short synthetic sequence from potassium phthalimide XXII, including mono-alkylation of the latter with 1,5-dibromopentane or 1,6-dibromohexane, treatment of the obtained bromo derivatives XXIIIa,b with sodium sulfite and conversion of the resulting sodium sulfonates XXIVA,b into the corresponding sulfonyl chlorides XXVa,b with PCl₅. The sulfonyl chloride XXVc was obtained using literature procedure.⁴₀
Scheme 10. Synthesis of Sulfonamide Amines Va-n

<table>
<thead>
<tr>
<th>No</th>
<th>n</th>
<th>R¹</th>
<th>R²</th>
</tr>
</thead>
<tbody>
<tr>
<td>XXVIa, Va</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XXVIb, Vb</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XXVIc, Vc</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XXVId, Vd</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XXVIIe, Ve</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XXVIIf, Vf</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XXVIIg, Vg</td>
<td>6</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No</th>
<th>n</th>
<th>R¹</th>
<th>R²</th>
</tr>
</thead>
<tbody>
<tr>
<td>XXVIb, Vb</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XXVIh, Vh</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XXVIIc, Vc</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XXVIIi, Vi</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XXVIIj, Vj</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XXVIIa, Vl</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XXVIIb, Vm</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XXVIIc, Vn</td>
<td>6</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SAR

Compound 1 and 2 (Figure 1) represent two distinct compound classes, which are bioisosters, both targeting the NAMPT enzyme. The common features in the two compounds are the pyridyl head-group, a functional group with hydrogen binding capabilities, a linker chain and an aromatic group in the end of the linker. With the aim of discovering new compounds with improved activity and toxicological properties the SAR of these compounds was explored by modification of the mentioned key structural elements (Figure 2).

Figure 2. Overview of the sequence of the described SAR work: 1) Modification of aromatic end group D to hydroxamic acid esters (compounds 4-12). 2) SAR for pyridyl head group A (comp. 10, 13). 3) SAR of hydrogen binding group B, replacement of cyanoguanidine with squaric acid and urea (comp. 26, 28, 29, 38 and 39). 4) Change of the hydroxamic acid ester for a preferred alkoxy sulphonamide or sulphonamide in D (e.g. 10 vs. 15, 26 vs. 31). 5) Optimisation of linker length C and end group for squaric acids (31-34 and 36) and urea derivatives (40-42 and 44). 6) Final optimisation of the cyanoguanidine series with a pyridyl head-group and an alkoxy sulphoneamide (comp. 17 and 20-25).

The primary determination of activity was performed using a WST-1 cell viability and proliferation assay in two cell lines, a breast cancer, MCF-7, and an ovarian carcinoma, A2780, cell line. The WST-1 assay determines the metabolic activity of the cells, in a process dependent on NADH as coenzyme, thus this assay will have a strong functional connection to the NAMPT inhibition.
Modification of aromatic end group

Initially, the aromatic end group of compound 2 was modified by preparing novel hydroxamic acid esters which immediately gave potent analogues in the in vitro test system, represented by the first hit compound 4 with nanomolar activity (Table 1 and Figure 3).

![Chemical structures](image)

**Figure 3.** Structures of molecular fragment B in Table 1, 3 and 4.

**Table 1. NAMPT inhibitors with a cyanoguanidine binding group**

<table>
<thead>
<tr>
<th>Cell line</th>
<th>A2780$^a$</th>
<th>MCF-7$^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound</td>
<td>R$^1$ n A</td>
<td>B$^b$ IC$\text{50}$, (mean, nM) SD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>1, APO866</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>2, CHS828</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>4</td>
<td>4-pyridyl</td>
<td>6</td>
</tr>
<tr>
<td>5</td>
<td>4-pyridyl</td>
<td>6</td>
</tr>
<tr>
<td>10</td>
<td>4-pyridyl</td>
<td>6</td>
</tr>
<tr>
<td>11</td>
<td>4-pyridyl</td>
<td>7</td>
</tr>
<tr>
<td>12</td>
<td>4-pyridyl</td>
<td>5</td>
</tr>
<tr>
<td>13</td>
<td>phenyl</td>
<td>6</td>
</tr>
<tr>
<td>14</td>
<td>4-pyridyl</td>
<td>6</td>
</tr>
<tr>
<td>15</td>
<td>4-pyridyl</td>
<td>6</td>
</tr>
<tr>
<td>16</td>
<td>3-pyridyl</td>
<td>6</td>
</tr>
<tr>
<td>17</td>
<td>4-pyridyl</td>
<td>6</td>
</tr>
<tr>
<td>18</td>
<td>4-pyridyl</td>
<td>6</td>
</tr>
<tr>
<td>19</td>
<td>4-pyridyl</td>
<td>7</td>
</tr>
<tr>
<td>20</td>
<td>4-pyridyl</td>
<td>5</td>
</tr>
<tr>
<td>21</td>
<td>4-pyridyl</td>
<td>6</td>
</tr>
<tr>
<td>22</td>
<td>4-pyridyl</td>
<td>6</td>
</tr>
<tr>
<td>23</td>
<td>4-pyridyl</td>
<td>6</td>
</tr>
<tr>
<td>24</td>
<td>4-pyridyl</td>
<td>5</td>
</tr>
<tr>
<td>25</td>
<td>4-pyridyl</td>
<td>6</td>
</tr>
</tbody>
</table>

\textsuperscript{a} Activities were determined in a WST-1 assay. \textsuperscript{b} See Figure 3. \textsuperscript{c} ND, not determined.

In the crystal structure of NAMPT co-crystallized with compound 1 a rather large binding region near the surface of the protein can be observed where the side chain end group of the ligand is placed.\textsuperscript{41,42} As in earlier work the published crystal structure of NAMPT co-crystallized with 1 was used as starting point for docking analysis.\textsuperscript{43} (PDB ID 2GVJ) which was carried out in Glide (further details in Experimentals). Previously, we found that different ligands for NAMPT had such similar geometric features that compound 2 and 5 could even be docked into the crystal structure of compound 1 \textit{without} removing the crystallographic water molecules in the active site.\textsuperscript{43} However, due to the much larger and more diverse set of ligands we chose to completely remove the crystallographic waters in the current study. In the supporting information we have included additional pictures showing the crystal structure.
with the crystallographic water molecules present and it is evident that only few water molecules penetrate the active site when the ligand is present.

When 1 was re-docked into the empty active it achieved the crucial hydrogen bonding to Ser275, albeit with a slightly longer distance (2.3Å) compared to the 1.8Å observed in the X-ray structure (Figure 4).

![Figure 4.](image)

**Figure 4.** Left: Illustration of 1 docked in the NAMPT X-ray structure (PDB id 2GVJ). Notice the lack of crystallographic waters in the binding cleft (additional orientations are included in the Supporting Information). Center: The pose of 1 observed in the X-ray with hydrogens added and waters removed. Right: The pose obtained by docking 1 into the “dry” active site of NAMPT.

Docking of compound 4 suggested a similar binding mode as compared to 1 (Figure 5) where the cyanoguanidine is capable of achieving a similar hydrogen bond to Ser275. Furthermore, the cyanoguanidine established two new hydrogen bonds to Asp219, which may serve as part of the explanation for the efficiency of this chemical motif.
Figure 5. Left: The conformation of 4 docked into the NAMPT active site (PDB id 2GVJ). Right: Close-up of the pyridine sandwich with the three hydrogen bonds made by the cyanoguanidine moiety.

To investigate the preferred binding orientation of the side chain in compound 4 the close alpha-methyl and alpha-benzyl analogues were prepared in an enantiomerically pure form. A stereochemical preference for the (S)-methyl derivative (6) was found, with a 40 times higher activity, as compared with the (R)-methyl derivative (7) (Table 2). However, this was not reflected in the calculated docking scores for the interaction which showed a reversed preference. The reasons for this discrepancy were not clear from visual inspection of the docked structures since they were virtually superimposable in spite of the difference in stereochemistry. Therefore we speculate that the observed difference in activity could be due to one of several factors that are not accounted for in simple docking calculations such as protein flexibility or different interactions with the hydrogen-bond network between enzyme and water molecules. The similarity in physico-chemical properties leads us to believe that the observed difference in not due to differences in pharmacokinetics. The activity difference was very small for the corresponding benzyl enantiomers (8, 9), probably due to the similar size of the binding end-groups in the molecule (Table 2). Thus, the docking analysis of these structures did not reveal any obvious
differences, or a preferred fit, of the enantiomers with the protein structure. Even though the chiral
derivatives were very potent with sub-nanomolar activity this compound group was not further explored
due to a generally low stability and rapid hydrolysis in mouse plasma (data not shown).

Table 2. NAMPT inhibitors with a chiral end group

<table>
<thead>
<tr>
<th>Cell line</th>
<th>A2780&lt;sup&gt;a&lt;/sup&gt;</th>
<th>MCF-7&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound</td>
<td>R</td>
<td>IC&lt;sub&gt;50&lt;/sub&gt;, (nM) SD</td>
</tr>
<tr>
<td>6</td>
<td>(S)-Me</td>
<td>0.08 ND&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>7</td>
<td>(R)-Me</td>
<td>3.9 ±0.64</td>
</tr>
<tr>
<td>8</td>
<td>(S)-Bn</td>
<td>0.32 ±0.03</td>
</tr>
<tr>
<td>9</td>
<td>(R)-Bn</td>
<td>0.22 ±0.28</td>
</tr>
</tbody>
</table>

<sup>a</sup> Activities were determined in a WST-1 assay. <sup>b</sup> ND, not determined.

An improvement of both stability and activity was found for the hydroxamic acid esters bearing an
additional substituent on the hydroxamic acid nitrogen, compounds 5, 10, 11 and 12 all exhibiting sub-
nM activities (Table 1). From the docked structures it is clear that these ligands are capable of spanning
the wide entrance of the cleft of the protein active site thereby increasing their binding affinities. At
present time it is unclear whether this increase is due to additional (non-specific) binding interactions
with the protein surface or that the increased binding is caused by a decreased number of accessible
conformations of the free ligands.

SAR for pyridyl head group
In earlier studies the pyridyl head-group in the parent compounds has been found essential for high activity.\(^2\) To investigate the importance of the head-group in this series a phenyl derivative, compound 13, was prepared and found approx. 1000-2000 times less potent as compared with the analogous compound 10 (Table 1). This large difference in activity is difficult to explain since the two head-groups (phenyl and pyridine) are both capable of sandwiching between Tyr18 and Phe193 (Figure 6).

**Figure 6.** Docking of 10 and 13 in the NAMPT X-ray structure (PDB id 2GVJ), where it is clear that the head groups are virtually superimposable.

To investigate this difference in more detail we carried out an analysis of the binding energy using density functional theory (DFT) in combination with the B3LYP functional with added dispersion corrections (DFT-d3).
Due to the computational demands of DFT-d3 the enzyme was reduced to an active site model consisting of Arg-196, B-chain Tyr-18, B-chain Asp-16, Asp 219, Phe-193, Arg-311, and Ser-275. The amino acids were truncated at the Cα in line with earlier work. Since the aim of the study was primarily to delineate the effect of the head group it was also decided to truncate the ligands in the spacer region so it consisted of just a single methyl group. A single-point energy calculation shows that the pyridine has an interaction energy that is 22 kJ/mol larger than for the corresponding structure with a phenyl as head-group, which is in qualitative agreement with the experimental results. In the cyanoguanidine series also the 4-pyridyl head group was compared with the analogues 3-pyridyl derivative, compound 15 vs. 16 (Table 1). This comparison showed a >10 fold activity preference for the 4-pyridyl group. A similar activity preference was found for other 4-pyridyl versus 3-pyridyl compound pairs (data not shown), but in this case the observation could not be explained by the DFT calculations since 4-pyridyl and 3-pyridyl head groups had a similar stabilization energy (within 1 kJ/mol). At present it is unclear whether more extended conformational sampling combined with e.g. advanced mixed quantum mechanics/molecular mechanics (QM/MM) calculations could delineate this interesting experimental difference in activity.

*SAR of hydrogen binding group*

The next structural modification made was a replacement of the cyanoguanidine with other hydrogen binding groups. There have been previous attempts to substitute the cyanoguanidine or amide group of compounds 1 and 2 with other groups retaining activity (Figure 1). In this investigation the most promising substitutions were found to be the squaric acid and urea analogues. The squaric acid compounds 26, 28, 29 (Table 3) and the urea and thiourea derivatives with a 3-picolyll head group, compounds 38 and 39 respectively (Table 4), both series with a hydroxamic acid ester end group, all were potent inhibitors of proliferation. As expected, docking of these structures showed that they too were capable of obtaining the crucial hydrogen-bonding interactions in the active site of NAMPT (Figure 7).
Figure 7. Compounds docked in the NAMPT X-ray structure (PDB id 2GVJ). Left: 26, a representative of the squaric acid series with dotted lines indicating the hydrogen bonds made to Ser275 and Asp219. Center: 38, the urea linker also allows hydrogen bonds to be made to Asp219. Right: 39, also the larger thiourea can be accommodated in the active site.

Squaric acids with similar side chains as the parent compounds 1 and 2 have been reported in the patent literature to have anti-proliferative activity. This finding suggests a further exploration of the squaric acid bioisosters with novel side chains.

Table 3. NAMPT inhibitors with a squaric acid binding group

<table>
<thead>
<tr>
<th>Compound</th>
<th>R¹</th>
<th>n</th>
<th>A</th>
<th>B</th>
<th>Cell line</th>
<th>IC₅₀, (mean, nM)</th>
<th>SD</th>
<th>IC₅₀, mean, (nM)</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>4-pyridyl</td>
<td>6</td>
<td>CO</td>
<td>4</td>
<td>A2780²⁶</td>
<td>0.03</td>
<td>±0.02</td>
<td>ND²⁶</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>4-pyridyl</td>
<td>6</td>
<td>SO₂</td>
<td>5</td>
<td>MCF-7²⁷</td>
<td>4.1</td>
<td>±2.2</td>
<td>21.6</td>
<td>±4.5</td>
</tr>
</tbody>
</table>
28  4-pyridyl  6  CO  6  0.29 ±0.32  12.3 ±5.0
29  4-pyridyl  5  CO  6  0.68 ±0.47  23 ±1.1
30  4-pyridyl  6  SO₂  7  0.73 ±0.03  10.8 ±2.3
31  4-pyridyl  6  SO₂  4  0.49 ±0.22  9 ±2.9
32  4-pyridyl  7  SO₂  4  0.49 ±0.17  8 ±5.2
33  4-pyridyl  5  SO₂  4  0.57 ±0.12  35.8 ±8.4
34  4-pyridyl  6  SO₂  10  0.59 ±0.35  13.7 ±2.4
35  4-pyridyl  6  SO₂  11  0.2 ±0.14  29.1 ±6.4
36  4-pyridyl  5  SO₂  10  0.38 ±0.05  46.3 ±6.3

**Table 4.** NAMPT inhibitors with a urea (thiourea) binding group

![Structure](image)

<table>
<thead>
<tr>
<th>Cell line</th>
<th>A2780&lt;sup&gt;a&lt;/sup&gt;</th>
<th>MCF-7&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound</td>
<td>R&lt;sup&gt;1&lt;/sup&gt; n A</td>
<td>B&lt;sup&gt;b&lt;/sup&gt; IC&lt;sub&gt;50&lt;/sub&gt;, (mean, nM) SD</td>
</tr>
<tr>
<td>37</td>
<td>4-pyridyl  6  SO₂  4</td>
<td>0.25 ±0.13 0.05 ±0.01</td>
</tr>
<tr>
<td>38</td>
<td>3-picolyl  6  CO  4</td>
<td>0.27 ±0.13 0.37 ±0.51</td>
</tr>
<tr>
<td>39</td>
<td>3-picolyl&lt;sup&gt;c&lt;/sup&gt; 6  CO  4</td>
<td>0.91 ±0.31 5.5 ±2.2</td>
</tr>
<tr>
<td>40</td>
<td>4-pyridyl  6  SO₂  7</td>
<td>0.56 ±0.01 1.4 ±0.05</td>
</tr>
<tr>
<td>41</td>
<td>3-picolyl  6  SO₂  7</td>
<td>0.17 ±0.06 0.93 ±0.11</td>
</tr>
<tr>
<td>42</td>
<td>4-pyridyl  5  SO₂  4</td>
<td>3.4 ±2.2 28 ±11.2</td>
</tr>
</tbody>
</table>

<sup>a</sup> Activities were determined in a WST-1 assay.  
<sup>b</sup> See Figure 3.  
<sup>c</sup> ND, not determined
<table>
<thead>
<tr>
<th></th>
<th>Compound</th>
<th>End Group</th>
<th>Ki (μM)</th>
<th>IC50 (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>43</td>
<td>4-pyridyl</td>
<td>SO₂</td>
<td>1.8 ±0.07</td>
<td>7.4 ±4.6</td>
</tr>
<tr>
<td>44</td>
<td>3-picolyl</td>
<td>SO₂</td>
<td>4.6 ±4.5</td>
<td>6.5 ±5.7</td>
</tr>
<tr>
<td>45</td>
<td>3-picolyl</td>
<td>SO₂</td>
<td>0.31 ±0.11</td>
<td>3.6 ±2.3</td>
</tr>
<tr>
<td>46</td>
<td>3-picolyl</td>
<td>SO₂</td>
<td>0.58 ±0.18</td>
<td>5.8 ±0.15</td>
</tr>
<tr>
<td>47</td>
<td>3-picolyl</td>
<td>SO₂</td>
<td>2.2 ±0.12</td>
<td>11 ±5.0</td>
</tr>
<tr>
<td>48</td>
<td>3-picolyl</td>
<td>SO₂</td>
<td>1.7 ±0.21</td>
<td>8.7 ±7.2</td>
</tr>
<tr>
<td>49</td>
<td>3-picolyl</td>
<td>SO₂</td>
<td>13 ±6.4</td>
<td>49 ±33.7</td>
</tr>
<tr>
<td>50</td>
<td>3-picolyl</td>
<td>SO₂</td>
<td>2.7 ±1.9</td>
<td>7 ±1.2</td>
</tr>
<tr>
<td>51</td>
<td>4-pyridyl⁹</td>
<td>SO₂</td>
<td>0.16 ±0.15</td>
<td>0.31 ±0.40</td>
</tr>
</tbody>
</table>

⁹ Activities were determined in a WST-1 assay. ¹ See Figure 3. ² The compound is a thiourea.

**Change of the hydroxamic acid ester**

With three structural core elements, the cyanoguanidine, the squaric acid and the urea, all producing highly active compounds, in hand a further optimization was structured. Changing the hydroxamic acid ester for an alkoxy sulphonamide or sulphonamide gave a more robust series of compounds with high activity and this substitution was used in the further SAR work (see e.g. 10 vs. 15, Table 1 and 26 vs. 31, Table 3).

**Squaric acid series**

In the squaric acid series, compounds 31, 34, and 35 were prepared to explore the effect of ring size in the end group, however, no significant difference in binding affinity/anti-proliferative activity was found (Table 3). This is understandable also from the docking results since the head groups dock in a similar position in the active site, as expected (Figure 8 left), whereas the flexible end of the chain can freely position itself in the wide entrance region of the catalytic cleft.
Figure 8. Compounds docked in the NAMPT X-ray structure (PDB id 2GVJ). Left: Compounds 31, 34, and 35 all dock into the sandwich region of the enzyme. Right: The wide entrance region allows the ligands to obtain different positions that do not offer any differences in activity between compounds having a 5-membered (green), 6-membered (red), or 4-membered ring (blue) as substituent on nitrogen. Likewise the linker length was varied from 5-7 carbons in compounds 31-33 and 34 vs. 36 which gave compounds with similar activity, however, with a slight activity preference for compounds with 6 carbons in the linker (Table 3). Shorter and longer linker chains gave compounds with lower anti-proliferative activity (data not shown).

For compounds 31-33 the docking analysis shows a preference for a hydrogen bond interaction between the sulphonamide moiety and His191. This enforces a constraint on the length between the sulphonamide and the pyridine head-group, which is suitable for a 6-carbon linker (31). The docking results showed that the shorter chain introduces strain in the structure (33) and the longer 7-carbon linker has to coil up to satisfy the distance requirement (32). However, we should stress that the similarity in the biological activity shows that such accommodation is possible and indeed takes place without significant loss in activity.
The squaric acid 27, a sulphone amide, was less active, however, this compound was not strictly analogous to any alkoxy sulphone amide since it has an additional pyridine group in the end group of the molecule. In all three series the sulphonamide end groups were found equipotent or slightly less potent as compared with similar alkoxy sulphonamide (see compounds 18, 23, 27 and 48, Table 1-4).

**Urea series**

The urea derivatives were designed as analogues to compound 1 where the unsaturated amide was replaced by a urea group. In this series, compounds with a 4-pyridyl or a 3-picolyl head-group were compared, compounds 40 vs. 41 and 42 vs. 44, and found equipotent despite the structural difference in the head group (Table 4). Computational modeling of these interactions showed that despite the difference in the location of the pyridine nitrogen the aromatic group positions itself perfectly aligned in the pocket between Tyr18 and Phe193. This introduces a slight difference in the orientation of the urea moiety, but does not hinder the formation of hydrogen bonds to Asp219. As mentioned earlier, our simple DFT model of the binding site does not reveal any differences in the π-π stacking ability of the two head groups which is in line with the observation for the urea series.

Similar to the squaric acid analogues a linker of 5-6 carbons gave highly active compounds both with a pyridyl head-group (37, 42, 43) and a picolyl head-group (46, 47, 49, 50, Table 4).

Also in the urea series many of the analogues showed sub nM activities either with a pyridyl or picolyl head-group, a urea or thio-urea binding group and a series of different end groupings.

**Cyanoguanidine series**

Returning to the cyanoguanidine series with a pyridyl head-group and an alkoxy sulphone amide connecting the linker and end groups the most potent compounds with low pM anti-proliferative activity, e.g. compounds 17 and 20-25, were found (Table 1). Similar to the other series a linker of 6 carbons was optimal.
In summary, using a functional cell proliferation assay a rather broad SAR was determined. Highly active compounds were found in all three series, the cyanoguanidine, the squaric acid and the urea series, suggesting an analogous interaction with the target NAMPT enzyme. Also, a similar substitution pattern was used to obtain the most potent compounds in the three series suggesting a similar binding to the target.

**In vitro activity and mode of action.**

To further characterize the key compounds, the IC$_{50}$ values of a number of them were established in the colon cancer cell line HCT-116 and a derived compound 1 resistant cell line HCT-116/APO866 (Table 5). Determination of the actual sensitivity of the cell line with acquired resistance was not possible. However, the resistance towards the compounds was at least 128-2632 fold higher in HCT-116/APO866 compared to the parental cell line. The mechanism of resistance in HCT-116/APO866 has been determined to be specifically due to a mutation, H191R, in the active site of NAMPT which results in highly specific resistance.$^{29,43}$ Thus, the high level of cross-resistance observed for the compounds in this study strongly suggests that their mechanism of action likewise is through inhibiting NAMPT and thus similar to that of compound 1.

### Table 5. IC$_{50}$ values for key compounds for anti-proliferative effects in HCT-116 and compound 1 resistant HCT-116/APO cells

<table>
<thead>
<tr>
<th>Cell line</th>
<th>HCT-116$^a$</th>
<th>HCT-116/APO866$^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound</td>
<td>IC$_{50}$ (nM) ±SD</td>
<td>IC$_{50}$ (nM)</td>
</tr>
<tr>
<td>1</td>
<td>10.9 6.1</td>
<td>946</td>
</tr>
<tr>
<td>15</td>
<td>1.9 0.2</td>
<td>&gt;5000</td>
</tr>
<tr>
<td>17</td>
<td>3.6 2.4</td>
<td>&gt;5000</td>
</tr>
<tr>
<td>31</td>
<td>39 13</td>
<td>&gt;5000</td>
</tr>
<tr>
<td>37</td>
<td>5.3 2.9</td>
<td>&gt;5000</td>
</tr>
</tbody>
</table>
Activities were determined in a WST-1 assay.

In order to confirm the on-target mechanism of action for the new series of compounds the enzyme inhibitory activity was determined using a NAMPT enzymatic assay with HepG2 lysates as source of NAMPT enzyme (Table 6). Even though the correlation with the anti-proliferative activity data was not perfect, all tested compounds showed high potency with low nM activity, thus a strong support for a direct enzyme interaction. The discrepancy between enzyme inhibition and anti-proliferative activity is suggested to be due to the different properties of the compounds such as cell penetration which is important in the cellular assay. Compounds were selected for further testing primarily based on in vitro activity but also to cover the chemical classes. Key compounds were also characterised in a clonogenic assay in several cancer cell lines (Table 7). Compounds 15 and 17 showed similar or increased potency in these assays as compared to reference compound 1 and were thus selected for further in vivo characterization.

Table 6. NAMPT enzyme assay (IC\textsubscript{50}, nM)

<table>
<thead>
<tr>
<th>Comp nr</th>
<th>1</th>
<th>2</th>
<th>4</th>
<th>5</th>
<th>10</th>
<th>11</th>
<th>14</th>
<th>15</th>
<th>17</th>
</tr>
</thead>
<tbody>
<tr>
<td>IC\textsubscript{50} (nM)</td>
<td>2.2</td>
<td>18.3</td>
<td>1.1</td>
<td>38.5</td>
<td>0.2</td>
<td>4.4</td>
<td>2.4</td>
<td>0.3</td>
<td>3.2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Comp nr</th>
<th>18</th>
<th>27</th>
<th>32</th>
<th>33</th>
<th>37</th>
<th>39</th>
<th>40</th>
<th>41</th>
</tr>
</thead>
<tbody>
<tr>
<td>IC\textsubscript{50} (nM)</td>
<td>2.4</td>
<td>22.8</td>
<td>3.6</td>
<td>49.6</td>
<td>49</td>
<td>8.2</td>
<td>133.2</td>
<td>11.8</td>
</tr>
</tbody>
</table>

Table 7. Clonogenic assay for compounds 15, 17 and 1 in a selection of cancer cell lines

<table>
<thead>
<tr>
<th>Compound, Cell line</th>
<th>15, IC\textsubscript{50} (nM)</th>
<th>17, IC\textsubscript{50} (nM)</th>
<th>1, IC\textsubscript{50} (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A2780</td>
<td>0.55 (24h)</td>
<td>0.43 (16h)</td>
<td>5.7</td>
</tr>
<tr>
<td>A431</td>
<td>&gt;50</td>
<td>ND\textsuperscript{a}</td>
<td>6.1</td>
</tr>
<tr>
<td>DU145</td>
<td>&gt;50</td>
<td>6.39</td>
<td>ND\textsuperscript{a}</td>
</tr>
</tbody>
</table>
In vivo antitumour activity.

Compounds with potent (nM) activity from all series were taken forward to tests of pharmacokinetics and preliminary toxicology effects in mouse as a selection filter for in vivo test in an A2780 xenograft mouse model (Table 8). Several of the new compounds compared well with the reference compound 1 and based on these data compounds were selected. Most compounds in these series exhibited a relatively short half-life, approximately 20 min, but with an adequate systemic exposure (AUC). Therefore, in this early screen for pharmacological activity in vivo the compounds were administered i.p. to secure a sufficient exposure of the compound in the animal.

Table 8. Toxicological and pharmacokinetic data for selected derivatives as determined in mouse

<table>
<thead>
<tr>
<th>Compound</th>
<th>Toxicology a</th>
<th>Dose for PK (mg/kg)</th>
<th>Route</th>
<th>Pharmacokinetics</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MTD (mg/kg)</td>
<td></td>
<td></td>
<td>T½ (hrs)</td>
</tr>
<tr>
<td>1</td>
<td>10&lt;MTD&lt;50</td>
<td>20 i.v.</td>
<td></td>
<td>0.4</td>
</tr>
<tr>
<td>15</td>
<td>MTD&lt;10</td>
<td>50 i.v.</td>
<td></td>
<td>0.18</td>
</tr>
<tr>
<td>17</td>
<td>10&lt;MTD&lt;50</td>
<td>50 i.v.</td>
<td></td>
<td>0.36</td>
</tr>
<tr>
<td>31</td>
<td>10&lt;MTD&lt;50</td>
<td>50 i.v.</td>
<td></td>
<td>0.21</td>
</tr>
<tr>
<td>37</td>
<td>MTD&lt;10</td>
<td>50 i.v.</td>
<td></td>
<td>0.45</td>
</tr>
</tbody>
</table>

a The compound toxicity (MTD) was estimated in NMRI mice dosing the compounds bid i.p. for 5 consecutive days, determining weight loss and blood cell counts.
Treatment with compound 17 (15 mg/kg bid i.p. for 10 consecutive days (small tumours) or two 5 day cycles (large tumours) had good therapeutic effect in both small and large A2780 tumours (Figure 9). A clear decrease was seen in the tumour volumes during the treatment period, some mice even showed a transient cure and eradication of the tumour. After treatment, the tumours resumed growth at various time points, and grew to the maximum allowed size (1000 mm$^3$). Treatment with compound 17, 15 mg/kg, using the schedules above was well tolerated and did not affect the body weight as compared with vehicle treated animals (Figure 9, insert).

Figure 9. Tumour growth curves of compound 17 in an A2780 xenograft mouse model. (15 mg/kg bid i.p. on days 0-4 + 7-11 (large tumours; starting volume 500 mm$^3$) or days 0-9 (small tumours; starting volume 100 mm$^3$). Inserted graph; body weight change during treatment.

Similarly, compound 15 was tested in the A2780 xenograft model with large tumours (3 mg/kg, i.p., bid, 10 consecutive days) (Figure 10). This compound (15) showed good efficacy and on average, treatment reduced the tumour volume significantly to one fifth of the volume from start of treatment (Figure 10A). This dose was found well tolerated in the mice (Figure 10C). Compound 15 was tested at higher
doses (5 and 10 mg/kg) with very clear therapeutic effects, however already at 5 mg/kg four of nine mice showed toxic signs in form of body weight loss and reduced activity level as compared to control which was further accentuated at 10 mg/kg (data not shown). Thus, it was concluded that a 3 mg/kg bid dose was at the MTD level for compound 15, in this model.
Figure 10. Treatment with compound 15, in an A2780 xenograft mouse model (large tumours, 3 mg/kg, i.p., bid). A) Mean tumour volume. B) Tumour volume in individual mice C) Body weight during treatment in individual mice.

In a comparative study with these two compounds (15 and 17) and the reference compound 1, compound 15 was found approximately 12 times more potent than 1 in the A2780 xenograft mouse model (schedule; i.p. bid day 0-4, starting tumour volume 100 mm$^3$) as measured by the tumour volume at day 14. Significant reduction of A2780 tumour volume at day 14 was observed after treatment with compound 15, 1.25 and 2.5 mg/kg and compound 1, 15 mg/kg. Dose response effect of 15, 0.63, 1.25 and 2.5 mg/kg was observed with percent volume of treated tumours versus control T/C% of 82, 40 and 24%, respectively. Also, some effect (T/C=52%), however not significant, was determined after
treatment with compound 17 and compound 1 (Figure 11). Critical body weight losses were not observed in any treatment groups.

In summary, in vivo the selected compounds showed an equal or increased potency as compared with reference compound 1, with no critical signs of toxicology using effective doses. These highly promising results suggest a continuation of studies of this compound class.

**Figure 11.** Tumour volume at day 14 after treatment with compounds 15 (0.63, 1.25, 2.5 mg/kg), 17 (15 mg/kg) and 1 (15 mg/kg) bid day 0-4 as compared with vehicle, in a A2780 xenograft mouse model.

**Conclusion**

The present study describes the successful discovery of novel NAMPT inhibitors with promising biological activities as anti-proliferative agents in cancer cell lines in vitro and potent tumour reduction efficacy in vivo in a xenograft mouse model. The structure based method used for the optimization of these structures gave a rationale for the obtained activities and knowledge about the scope and limitation in the design of new NAMPT inhibitors. The most active compounds in these new series compared
favorably, in respect to toxicology and in vivo activity, with compounds already in the clinic and warrant further investigation as promising lead molecules for the inhibition of NAMPT.

**Experimentals**

Reaction conditions and yields were not optimized. $^1$H and $^{13}$C NMR spectra were recorded on a Bruker Avance 300 spectrometer (300 MHz) or Varian 400 OXFORD NMR spectrometer (400 MHz).

Chemical shifts are reported in parts per million (δ) and referenced to hexamethyldisiloxane (HMDSO) as an internal standard or using the signal according to deuterated solvent for $^1$H spectra (CDCl$_3$, 7.26; CD$_3$OD, 3.31; (CD$_3$)$_2$SO, 2.50) and $^{13}$C spectra (CDCl$_3$, 77.23; CD$_3$OD, 49.00; (CD$_3$)$_2$SO, 39.52). The value of a multiplet, either defined (dublet (d), triplet (t), double dublet (dd), double triplet (dt), quartet (q)) or not (m) at the approximate mid-point is given unless a range is quoted. (bs) indicates a broad singlet. MS was performed using an LC-MS using a Bruker Esquire 3000+ ESI Ion-trap with an Agilent 1200 HPLC-system or on an Acquity UPLC system (Waters) connected to the Micromass Q-TOF micro hybrid quadrupole time of flight mass spectrometer operating in the electrospray ionization (ESI) positive ion mode and using reverse-phase Acquity UPLC BEH C18 column (1.7μm, 2.1×50 mm) on a gradient of 5-98% acetonitrile-water 0.1% formic acid. All tested compounds were of sufficient purity (>95%) as determined by HPLC, using an Agilent 1200 HPLC-system. HRMS was carried out on a Micromass Q-Tof micro mass spectrometer. Elemental analyses were performed on Carlo Erba CHNS-O EA-1108 apparatus. Melting points were measured on a “Boetius” or Gallenkamp melting point apparatus and are uncorrected. Silica gel, 0.035 e 0.070 mm, (Acros) was employed for column chromatography.

**Preparation of key compounds 15 and 17.**
For a full description of the preparation and spectroscopic data of compounds reported in this paper please view Supporting Information.

6-(2-Cyano-3-(pyridin-4-yl)guanidino)-N-cyclohexyl-N-(2-morpholinoethoxy)hexane-1-sulfonamide (15)

2-(2-Morpholinoethoxy)isoindoline-1,3-dione (XIVc)

Synthesis of compound XIVc by modified version of published procedures46-48 was performed as follows: To a mixture of 2-hydroxyisoindoline-1,3-dione (33.92 g, 208 mmol) and 4-(2-chloroethyl)morpholine hydrochloride (50.24 g, 270 mmol) in 1-methyl-2-pyrrolidinone (160 ml) slowly was added DBU (80 ml, 535 mmol) and the resulting mixture was stirred at 45°C for 6 h. The mixture was poured into water (500 ml), extracted with ethyl acetate (3 × 250 ml), the combined extract was washed with brine (200 ml), and dried (Na₂SO₄). The solvent was evaporated and the residue was dried in vacuo to give compound XIVc (39.0 g, 68%) as an oil which solidified on standing. ¹H NMR (200 MHz, CDCl₃) δ 2.50 (m, 4H), 2.79 (t, J = 5.5 Hz, 2H), 3.59 (m, 4H), 4.37 (t, J = 5.5 Hz, 2H), 7.70-7.89 (m, 4H).

O-(2-Morpholinoethyl)hydroxylamine (VIIIe)

To a solution of 2-(2-morpholinoethoxy)isoindoline-1,3-dione (XIVc) (39.0 g, 141 mmol) in a mixture of methanol (200 ml) and dichloromethane (100 ml) was added hydrazine hydrate (20 ml, 411 mmol) and the obtained mixture was stirred at room temperature overnight. The resulting precipitate was filtered off and the filtrate was concentrated in vacuo. The residue (22.9 g) was mixed with water (200 ml), to this mixture was added conc. HCl (30 ml), and the solid material was filtered off. The filtrate was washed with EtOAc (200 ml) and the pH of the medium was raised to 10 by adding 5N aqueous NaOH. The mixture was extracted with chloroform (3 × 300 ml), the extract was washed with brine (100 ml), and dried (Na₂SO₄). The solvent was evaporated and the residue was dried in vacuo to give O-(2-morpholinoethyl)hydroxylamine (VIIIe) (20.7 g, quantitative yield). ¹H NMR (200 MHz, CDCl₃) δ: 2.44-2.55 (m, 4H); 2.59 (t, J = 5.4 Hz, 2H); 3.69-3.77 (m, 4H); 3.81 (t, J = 5.4 Hz, 2H); 5.50 (b s, 2H).
Cyclohexanone O-(2-morpholin-4-yethyl)oxime (XIXd)

To a stirred solution of cyclohexanone oxime (XVIIc) (22.64 g, 0.2 mol) in dimethylformamide (200 ml) at ice-bath temperature 60% sodium hydride in mineral oil (16.0 g, 0.4 mol) was added portion-wise and the resulting mixture was stirred at this temperature for 1 h. To the reaction mixture was added a suspension of 4-(2-chloroethyl)morpholine (37.22 g, 0.2 mol) in dimethylformamide (100 ml). The ice-bath was removed, the reaction mixture was stirred at room temperature for 16 h and at 60 °C for 3 h. The mixture was allowed to cool to room temperature, and then filtered and the filtrate was evaporated. The residue was mixed with a saturated ammonium chloride solution in water (300 ml) and extracted with diethyl ether (3 × 200 ml). The combined organic extracts were washed successively with 0.5 N sodium hydroxide (200 ml), brine (200 ml), and dried (Na₂SO₄). The solvent was evaporated and the residue (36.47 g) was chromatographed on silica gel (250 g) with chloroform-methanol (40 : 1) as eluent to give compound XIXd (35.1 g, 77.5%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 1.54-1.71 (m, 6H), 2.18 (m, 2H), 2.43 (m, 2H), 2.52 (m, 4H), 2.66 (t, 2H, J = 5.8 Hz), 3.71 (m, 4H), 4.15 (t, 2H, J = 5.8 Hz).

4-{2-[(Cyclohexylamino)oxy]ethyl}morpholine (VIIIc)

To a solution of cyclohexanone O-(2-morpholin-4-yethyl)oxime (XIXd) (13.9 g, 61.4 mmol) in methanol (100 ml) at ice-bath temperature were added sodium cyanoborohydride (7.72 g, 122.8 mmol) and trace of Methyl Orange. To the obtained slightly yellow solution slowly 2N HCl solution in methanol was added until the color of the reaction mixture changed from yellow to pink (in about 15 min.). The reaction mixture was stirred at room temperature for 5 h and the solvent was evaporated. To the residue was added water (30 ml) and the pH of the obtained solution was raised to pH>9 with 6N KOH, saturated with sodium chloride. The obtained mixture was extracted with chloroform (3 × 150 ml), the combined organic extract was washed with brine (100 ml), and dried (Na₂SO₄). The solvent was removed and the residue was dried in vacuo to afford title compound VIIIc (13.0 g, 92%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 1.00-1.33 (m, 5H), 1.62 (m, 1H), 1.73 (m, 2H), 1.84 (m, 2H),
2.48 (m, 4H), 2.56 (t, 2H, J = 5.7 Hz), 2.84 (tt, 1H, J = 3.7, 10.5 Hz), 3.71 (m, 4H), 3.81 (t, 2H, J = 5.7 Hz), 5.43 (br s, 1H). LCMS (ESI) m/z: 299 [M+H]+.

**Sodium 6-(1,3-dioxo-1,3-dihydro-2H-isooindol-2-yl)-1-hexanesulfonate (XXIVb)**

To a hot solution of 2-(6-bromohexyl)-1H-isooindole-1,3(2H)-dione (XXIIIb)\(^\text{49}\) (12.67 g, 40.8 mmol) in ethanol (82 ml) was added a solution of sodium sulfite (10.3 g, 81.7 mmol) in water (80 ml) and the resulting mixture was refluxed overnight. The hot mixture was filtrated, crystallized from ethanol, and dried in vacuo over P\(_2\)O\(_5\) to give compound XXIVb (8.43 g, 62%). \(^1\)H NMR (200 MHz, (CD\(_3\))\(_2\)SO) \(\delta\) 1.16-1.41 (m, 4H), 1.41-1.68 (m, 4H), 2.37 (m, 2H), 3.56 (t, 2H, J = 7.0 Hz), 7.77-7.92 (m, 4H). LCMS (ESI): m/z 312 [M-sulfonic acid +H]+.

**6-(1,3-Dioxo-1,3-dihydro-isooindol-2-yl)-hexanesulfonyl chloride (XXVb)**

A mixture of sodium 6-(1,3-dioxo-1,3-dihydro-2H-isooindol-2-yl)-1-hexanesulfonate (XXIVb) (13.99 g, 42.0 mmol) and phosphorus pentachloride (28.0 g, 134.5 mmol) was carefully ground in a mortar (Caution – a good hood has to be used!). An evaluation of some amount of gas was observed and gradually (in 2-3 min.) the solid mixture turned into an oily liquid. The obtained liquid was mixed with toluene (280 ml), the precipitated solid material was filtered off, washed with toluene, and the filtrates were combined. The solvent was evaporated and the residue was azeotropically dried several times with toluene. The obtained white solid was dissolved in ethyl acetate (300 ml), washed successively with water (100 ml), saturated sodium bicarbonate (2 \(\times\) 100 ml), brine (2 \(\times\) 100 ml), and dried (Na\(_2\)SO\(_4\)). The solvent was evaporated and the residue was dried in vacuo over P\(_2\)O\(_5\) to afford compound XXVb (10.4 g, 75%) as white crystals: mp 73-75°C. \(^1\)H NMR (400 MHz, CDCl\(_3\)) \(\delta\) 1.41 (qui, 2H, J = 7.6 Hz), 1.55 (qui, 2H, J = 7.6 Hz), 1.72 (qui, 2H, J = 7.4 Hz), 2.04 (m, 2H); 3.65 (m, 2H); 3.69 (t, 2H, J = 7.1 Hz); 7.67-7.75 (m, 2H); 7.80-7.87 (m, 2H). Anal. Calcd. for C\(_{14}\)H\(_{16}\)ClNO\(_4\)S: C, 50.99; H, 4.89; N, 4.25; S, 9.72. Found: C, 51.03; H, 5.01; N, 4.17; S, 9.68.

**N-Cyclohexyl-6-(1,3-dioxo-1,3-dihydro-2H-isooindol-2-yl)-N-(2-morpholinoethoxy)-1-hexanesulfonamide (XXVIe)**
A solution of N-cyclohexyl-O-(2-morpholin-4-yl-ethyl)-hydroxylamine (VIIIc) (12.56 g, 55 mmol) and triethylamine (14.0 ml, 100 mmol) in dry dichloromethane (100 ml) under argon atmosphere was cooled to -20°C. To the stirred solution slowly during 1 h was added a solution of 6-(1,3-dioxo-1,3-dihydro-2H-isoinodol-2-yl)hexane-1-sulfonyl chloride (XXVb) (16.49 g, 50 mmol) in dichloromethane (50 ml), and the resulting mixture was stirred at -20 °C for 20 h. The reaction mixture was concentrated to a small volume, filtered, and the precipitated solid material was washed with dichloromethane. The filtrate was evaporated, the residue (32.25 g) was dissolved in a small volume of chloroform and chromatographed on silica gel (450 g) with hexane-isopropanol (gradient from 7:3 to 6:4) as eluent. The eluate, containing pure product by TLC, was separated, and the impure material was rechromatographed using the same eluent. The eluates with TLC pure material were combined, the solvent was evaporated, and the residue was dried in vacuo to afford compound XXVe (16.4 g, 62.8%) as a crystalline solid. 1H NMR (400 MHz, CDCl3) δ 1.10 (tq, 1H, J = 3.5, 12.9 Hz), 1.20-1.44 (m, 4H), 1.44-1.76 (m, 7H), 1.76-1.95 (m, 6H), 2.49 (m, 4H), 2.58 (t, 2H, J = 5.6 Hz), 3.08 (b s, 2H); 3.58 (tt, 1H, J = 3.6, 11.7 Hz), 3.68 (t, 2H, J = 7.0 Hz), 3.69 (m, 4H), 4.12 (b s, 2H), 7.71 (m, 2H), 7.83 (m, 2H).

6-Amino-N-cyclohexyl-N-(2-morpholinoethoxy)-1-hexanesulfonamide (Ve)

N-Cyclohexyl-6-(1,3-dioxo-1,3-dihydro-2H-isoinodol-2-yl)-N-(2-morpholinoethoxy)-1-hexanesulfonamide (XXVe) (17.608 g, 33.75 mmol) was dissolved in a mixture of chloroform (150 ml) and absolute ethanol (150 ml), and hydrazine hydrate (4.2 ml, 86.54 mmol) was added. The obtained mixture was refluxed for 5 h, and then stirred at room temperature overnight. The mixture was filtered, the precipitate was washed with dichloromethane, and the combined filtrates were evaporated. The residue was dissolved in dichloromethane (50 ml) and the mixture was kept in a refrigerator (ca 5 °C) for 1 h, and then filtered again. The filtrate was evaporated and the residue (14.392 g) was chromatographed on silica gel (200 g) with methanol-30% ammonium hydroxide aqueous solution (gradient from 25:1 to 20:1) to give 8.38 g of an oil. The oil was dissolved in dichloromethane (100 ml), washed successively with water (2 × 20 ml), brine (20 ml), and dried (Na2SO4). The solvent was evaporated and the residue was dried in vacuo at 50 °C to give compound Ve (7.67 g, 63.8%) as a
yellow oil. \(^1\)H NMR (400 MHz, CDCl\(_3\)) \(\delta\) 1.10 (tq, 1H, \(J = 3.4, 12.9\) Hz), 1.20-1.52 (m, 8H), 1.52-1.69 (m, 5H), 1.75-1.98 (m, 6H), 2.49 (m, 4H), 2.59 (t, 2H, \(J = 5.6\) Hz), 2.70 (t, 2H, \(J = 6.8\) Hz), 3.09 (b s, 2H); 3.59 (tt, 1H, \(J = 3.6, 11.7\) Hz), 3.69 (m, 4H), 4.12 (b s, 2H). LCMS (ESI) \(m/z\): 392 [M+H]\(^+\). Anal. Calcd for C\(_{18}\)H\(_{37}\)N\(_3\)O\(_4\)S \(\cdot 0.15\) H\(_2\)O: C, 54.83; H, 9.54; N, 10.66; S, 8.13. Found: C, 54.86; H, 9.66; N, 10.63; S, 8.14.

6-(2-Cyano-3-(pyridin-4-yl)guanidino)-N-cyclohexyl-N-(2-morpholinoethoxy)hexane-1-sulfonamide (15)

A mixture of 6-amino-N-cyclohexyl-N-(2-morpholinoethoxy)-1-hexanesulfonamide (Ve) (2.49 g, 6.4 mmol), 4-[(cyanoimino)(methylsulfanyl)methyl]aminopyridine (IIa) (1.22 g, 6.3 mmol), triethylamine (3 ml, 21.6 mmol), and 4-dimethylaminopyridine (0.1 g, 0.8 mmol) in dry pyridine (4 ml) was stirred at 75-80 °C for 5 h. The solvent was evaporated to dryness and the residue was chromatographed on silica gel (150 g) with acetonitrile-water (10:1) as eluent to give compound 15 (1.8 g, 53%) as a foam together with a less pure material (1.0 g, 29%) which can be purified repeatedly by column chromatography to increase the yield of the process. \(^1\)H NMR (200 MHz, (CD\(_3\))\(_2\)SO) \(\delta\) 0.79-1.66 (m, 13H); 1.66-1.96 (m, 5H); 2.38-2.47 (m, 4H); 2.47-2.60 (m, 2H, overlapped with DMSO); 3.12-3.33 (m, 4H); 3.39-3.54 (m, 1H); 3.52-3.63 (m, 4H); 4.02 (t, \(J = 5.6\) Hz, 2H); 7.21 (d, \(J = 5.3\) Hz, 2H); 7.87 (t, \(J = 5.5\) Hz, 1H); 8.38 (d, \(J = 5.6\) Hz, 2H); 9.41 (b s, 1H). HRMS \(m/z\) calcd for C\(_{25}\)H\(_{42}\)N\(_7\)O\(_4\)S [M+H]\(^+\), 536.3019; found, 536.2976.

6-(2-Cyano-3-(pyridin-4-yl)guanidino)-N-(cyclohexylmethoxy)-N-(2-fluoroethyl)hexane-1-sulfonamide (17)

\(N\)-(Cyclohexylmethoxy)-6-(1,3-dioxo-1,3-dihydro-2H-isooindol-2-yl)-1-hexanesulfonamide (XXVIIc)

To a solution of \(O\)-(cyclohexylmethyl)hydroxylamine (VIII\(_d\)) (1.1 g, 8.51 mmol) and triethylamine (2.3 ml, 16.55 mmol) in dry dichloromethane (40 ml) at ice-bath temperature slowly for 2 h was added 6-(1,3-dioxo-1,3-dihydro-2H-isooindol-2-yl)hexane-1-sulfonyl chloride (XXVb) (3.08 g, 9.34 mmol) portion-wise. The reaction mixture was allowed gradually to warm up to room temperature (for 1 h) and
evaporated. The residue was dissolved in ethyl acetate (100 ml), washed successively with water (2 × 15 ml), brine (30 ml), and dried (Na₂SO₄). The solvent was evaporated and the residue was dried in vacuo over P₂O₅ to afford compound **XXVIIc** (3.2 g, 89%) as crystalline solid. ¹H NMR (400 MHz, CDCl₃) δ 0.86-1.00 (m, 2H), 1.08-1.30 (m, 3H), 1.33-1.44 (m, 2H), 1.46-1.57 (m, 3H), 1.61-1.77 (m, 7H), 1.75-1.85 (m, 2H), 3.18 (m, 2H), 3.68 (t, 2H, \(J = 7.2\) Hz), 3.80 (d, 2H, \(J = 6.2\) Hz), 6.99 (s, 1H), 7.71 (m, 2H), 7.84 (m, 2H).

**N-(Cyclohexylmethoxy)-6-(1,3-dioxo-1,3-dihydro-2H-isooindol-2-yl)-N-(2-fluoroethyl)-1-hexanesulfonamide (XXVII)**

To a solution of N-(cyclohexylmethoxy)-6-(1,3-dioxo-1,3-dihydro-2H-isooindol-2-yl)-1-hexanesulfonamide (**XXVIIc**) (2.11 g, 5.0 mmol), 2-fluoroethanol (0.4 g, 6.2 mmol), and triphenylphosphine (2.16 g, 8.2 mmol) in dichloromethane (40 ml) at ice bath temperature slowly in 10 min. was added a solution of diethyl azodicarboxylate (1.43 g, 8.2 mmol) in dichloromethane (1.5 ml) and the resulting mixture was stirred at this temperature for 20 min. The ice bath was removed, and then the reaction mixture was stirred at room temperature for 3 h, and evaporated. The residue was mixed with petroleum ether-ethyl acetate (4:1, 25 ml), the obtained suspension was stirred for 30 min. at ice bath temperature and filtered. The filtrate was evaporated and the residue was chromatographed on silica gel with toluene-ethyl acetate (9:1) as eluent to afford compound **XXVIIi** (1.57 g, 67%) as white crystals. ¹H NMR (400 MHz, CDCl₃) δ 0.90-1.06 (m, 2H), 1.09-1.33 (m, 4H), 1.33-1.45 (m, 2H), 1.45-1.79 (m, 9H), 1.83-1.95 (m, 2H), 3.07 (m, 2H), 3.54 (td, 2H, \(J = 5.0, 23.8\) Hz), 3.68 (t, 2H, \(J = 7.1\) Hz), 3.86 (d, 2H, \(J = 6.4\)), 4.62 (td, 2H, \(J = 5.0, 47.1\) Hz), 7.71 (m, 2H), 7.83 (m, 2H).

**6-Amino-N-(cyclohexylmethoxy)-N-(2-fluoroethyl)-1-hexanesulfonamide (Vi)**

N-(Cyclohexylmethoxy)-6-(1,3-dioxo-1,3-dihydro-2H-isooindol-2-yl)-N-(2-fluoroethyl)-1-hexanesulfonamide (**XXVII**i) (1.53 g, 3.26 mmol) was dissolved in a mixture of ethanol (20 ml) and chloroform (10 ml), and hydrazine hydrate (0.5 ml, 103 mmol) was added. The reaction mixture was stirred at 60 °C for 2 h, left overnight at room temperature, and cooled in the refrigerator (5 °C). The precipitated solid was filtered off and the filtrate was evaporated. The residue was chromatographed on
silica gel with chloroform-methanol-30% ammonium hydroxide aqueous solution (5:1:0.15) as eluent to
give compound Vi (0.93 g, 84%) as white crystals. $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 0.90-1.04 (m, 2H),
1.09-1.30 (m, 3H), 1.33-1.54 (m, 6H), 1.54-1.78 (m, 6H), 1.82-2.02 (m, 4H), 2.72 (t, 2H, $J$ = 6.9 Hz),
3.08 (m, 2H), 3.54 (td, 2H, $J$ = 5.0, 23.6 Hz), 3.87 (d, 2H, $J$ = 6.5), 4.62 (td, 2H, $J$ = 5.0, 47.0 Hz).

**6-(2-Cyano-3-(pyridin-4-yl)guanidino)-N-(cyclohexylmethoxy)-N-(2-fluoroethyl)hexane-1-
sulfonamide (17)**

A mixture of 6-amino-N-(cyclohexylmethoxy)-N-(2-fluoroethyl)-1-hexanesulfonamide (Vi) (1.95 g,
5.76 mmol), 4-[(cyanoimino)(methylsulfanyl)methyl]aminopyridine (IIIa) (1.1 g, 5.76 mmol),
triethylamine (0.93 ml, 6.68 mmol), and 4-dimethylaminopyridine (0.15 g, 1.22 mmol) in dry pyridine
(20 ml) was stirred at 85 °C for 20 h. The solvent was evaporated to dryness; the residue was
azeotropically dried with toluene (2 × 5 ml), and then vigorously stirred with ether (30 ml) until the
precipitation occurred ($ca$ 2h). The obtained suspension was filtered and the solid material (2.7 g) was
chromatographed on silica gel with chloroform-methanol-30% ammonium hydroxide aqueous solution
(6:1:0.015) as eluent to give compound 17 (2.48 g, 89%) as white crystals: mp 100-102 °C. $^1$H NMR
(400 MHz, CDCl$_3$) $\delta$ 0.90-1.04 (m, 2H), 1.11-1.29 (m, 3H), 1.41 (qui, 2H, $J$ = 7.3 Hz), 1.48-1.75 (m,
10H), 1.91 (qui, 2H, $J$ = 7.6 Hz), 3.09 (t, 2H, $J$ = 7.5 Hz), 3.36 (q, 2H, $J$ = 6.6 Hz), 3.52 (dt, 2H, $J$ = 4.9,
24.0 Hz), 3.86 (d, 2H, $J$ = 6.5 Hz), 4.61 (dt, 2H, $J$ = 4.9, 47.0 Hz), 5.51 (b s, 1H), 7.20 (d, 2H, $J$ = 4.9
Hz), 7.68 (b s, 1H), 8.55 (d, 2H, $J$ = 4.9 Hz). Anal. Calcd for C$_{22}$H$_{35}$FN$_6$O$_3$S: C, 54.75; H, 7.31; N,
17.41. Found: C, 54.85; H, 7.42; N, 17.50. HRMS $m/z$ calcd for C$_{22}$H$_{36}$FN$_6$O$_3$S [M+H]$^+$, 483.2554;
found, 483.2526.

**Cell culture**

Human breast carcinoma, MCF-7 and ovarian carcinoma A2780 were grown according to American
Type Culture Collection guidelines. Cell culture media were from Invitrogen unless otherwise stated.
MCF-7 was maintained in DMEM and A2780 in RPMI 1640 with GlutaMax. Media was supplemented
with 10%(v/v) FCS (Perbio, Thermo Fischer Scientific) and penicillin (100 U/mL), streptomycin (0.1 mg/mL) and cells incubated at 37 °C in an atmosphere containing 5% CO₂.

**WST-1 proliferation assay**

Cells were seeded in 96-well plates (3×10³ cells/well) in culture medium (100 µL). The following day compounds were serially diluted in culture medium and 100 µL of each dilution were added per well in triplicate to the cell culture plates. Plates were incubated (72 h, 37°C, 5% CO₂ atmosphere) and the number of viable cells assessed using cell proliferation reagent WST-1 (Roche, Mannheim, Germany). Reagent (10 µL) was added to each well and after a 1 h incubation period, absorbance was measured at 450 nm subtracting absorbance at 690 nm as a reference. Data were analysed using GraphPad Prism (GraphPad Software, CA, USA) and CalcuSyn (Biosoft, Cambridge, UK) as appropriate.

**Clonogenic assays**

HCT116/APO866 resistant cell line was obtained as described previously.⁴³ In vitro colony forming assays were performed essentially as previously published.⁵⁰ Briefly, HCT116 cells were cultured with compounds for the indicated times and seeded onto 35 mm dishes in agar (3% (w/v)) containing a sheep erythrocyte feeder layer. Agar plates were cultured for 14–21 days at 37 °C and colonies counted using a digital colony counter and Sorcerer image analysis software (Perceptive Instruments Ltd, SuVolk, UK). Data were analyzed using GraphPad Prism (GraphPad Software, CA, USA) and CalcuSyn (Biosoft, Cambridge, UK) as appropriate.

**NAMPT enzyme assay**

NAMPT enzyme activity was measured as described previously with minor modifications.⁵¹,⁵² In this procedure the NAMPT catalysed formation of ¹⁴C-nicotinamide mononucleotide (NMN) was determined, using ¹⁴C-nicotinamide and 5-phosphoribosyl-1-pyrophosphate (PRPP) as substrates.
For preparation of lysates, confluent HepG2 cells were washed twice with PBS (4°C, Ca²⁺, Mg²⁺ free), once with NaHPO₄-buffer, (0.01 N, pH 7.4) and scraped in NaHPO₄-buffer. After centrifugation (10 min, 500×g, 4°C) pelleted cells were resuspended by pipetting in NaHPO₄-buffer to a concentration of approx. 10⁷ cells/100 µl for HepG2 and aliquoted (200 µl aliquots in 2 ml tubes). Cells were then broken up by sonography on ice (Bandelin Sonopuls, 3×10s, approx. 30% power). Cell debris was removed by centrifugation (23,000×g, 90 min, 0°C). Protamine sulphate solution (1% in NaHPO₄ buffer) was added to the supernatant (70 µl/ml supernatant) to precipitate DNA by incubation on ice for 15 min. After centrifugation (23,000×g, 30 min, 0°C), aliquots of the supernatant were stored at –80°C.

Various concentrations of inhibitor or adequate concentrations of DMSO as solvent control and cell lysates (10 µl) were added to a total of 50 µl reaction mixture (50 mmol/l TrisHCl pH 7.4; 2 mmol/l ATP; 5 mmol/l MgCl₂; 0.5 mmol/l PRPP; 6.2 µmol/l ¹⁴C-nicotinamide; American Radiolabelled Chemicals, St. Louis; MO, USA) and incubated (37°C, 1h). The reaction was terminated by transfer into tubes containing acetone (2 ml). The whole mixture was then pipetted onto acetone-pre-soaked glass microfiber filters (GF/A Ø 24 mm; Whatman, Maidstone, UK). After rinsing with acetone (2×1 ml), filters were dried, transferred into vials with scintillation cocktail (6 ml, Betaplate Scint, PerkinElmer, Waltham, MA, USA) and radioactivity of ¹⁴C-NMN was quantified in a liquid scintillation counter (Wallac 1409 DSA, Perkin Elmer). After subtraction of blank values, NAMPT activity was normalized to total protein as measured by BCA assay (Pierce).

**Xenograft studies**

The anti-tumour effect in vivo was tested in an A2780 (ovarian cancer) subcutaneous (s.c.) xenograft model in nude mice (female, NMRI/nude, Harlan or Taconic). Cancer cells were grown in RPMI + 10% FBS, washed once with PBS and suspended in 100 µL of PBS + 100 µL matrigel (BD) and injected s.c. Treatment started at tumour volumes around 100 mm³ (small tumours) or 500 mm³ (large tumour). The compounds were formulated in DMSO 2%, 20% HP-β-CD and isotonic saline at 10 mL/kg i.p.
injection. Tumour diameters were measured during tumour growth and tumour volumes (Tv) estimated according to the formula: \(Tv = \frac{\text{width}^2 \times \text{length}}{2}\). Mice were observed for tumour regression after 1 week or else sacrificed. The experiments were conducted at Topotarget A/S, Copenhagen and approved by the Experimental Animal Inspectorate, Danish Ministry of Justice.

**Pharmacokinetic analysis**

Mouse plasma samples were prepared for analysis by protein precipitation on Sirocco plates (Waters, Milford, Ma, USA). Waters Acquity UPLC system with Quattro Premier MS-MS system was used for separation and detection. Acetonitrile containing 1 µg/ml of internal standard was used in the ratio 3:1 (v/v) for precipitation. Separation was performed with an acetonitrile – 0.05% formic acid gradient on a Acquity UPLC BEH C18, 2.1×50 mm, 1.7 µm reversed phase column (Waters A/S) operated at 40°C. Detection was performed using electrospray MRM in the positive mode. Pharmacokinetic parameters were calculated using non compartmental analysis methods as included in WinNonlin ver 5.02 (Pharsight, CA, USA).

**Docking analysis**

The structure was downloaded from the protein data bank (PDB ID 2GVJ) and prepared for docking using the built-in protein preparation wizard in Maestro v. 9.3. During this process bond orders were assigned and hydrogens added to the crystal structure. Furthermore, the four seleno-methionines which had been incorporated to allow for better X-ray diffraction were changed to cysteines (chain A: residues 368 and 372, chain B: residues 368 and 372). The docking was carried out using Glide v. 5.8 in extra precision (XP) mode. The ligands were docked flexibly and nitrogen inversions and ring flips were allowed. The van der Waals radii of the non-polar ligand atoms (partial charge < 0.15) were scaled by a factor of 0.8 to accommodate slightly inaccurate initial dockings. A post-docking minimization was carried out for the best 25 poses for each ligand and finally the 10 best poses were reported.
DFT analysis

This study was carried out using Jaguar v. 8.0. DFT using the B3LYP functional with added d3 corrections to account for dispersion interactions. We used the 6-31G** basis set throughout.

Supporting Information Available. Experimental procedures, analytical and spectral data for all intermediate and final compounds, computation chemistry docking scores and associated docking poses. This material is available free of charge via the Internet at http://pubs.acs.org.

Corresponding Author

*Fredrik Björkling, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark, fb@sund.ku.dk, phone: +45 35 33 62 31, fax: +45 35 33 60 41

Present Address


S.J.N., Nuevolotion A/S 2100 Copenhagen, Denmark. P.B.J., Medical Prognosis Institute, 2970 Hørsholm, Denmark.

Notes

Authors K.D.E. and J.T. are employees of Topotarget A/S. Authors M.K.C., U.H.O., A.T., S.J.N., M.S., P.B.J. and F.B. are previous employees of Topotarget A/S.

Acknowledgment
We thank Anja Barnikol-Oettler for expert technical assistance with the NAMPT enzymatic assay and support from the German Research Council (DFG, KFO152-TP7) and the Leipzig LIFE (LIFE Health and Child Obesity) program to W.K. P.F. was supported by a Sapare Aude grant from the Danish Council for Independent Research no. 11-105487. We thank Nicolaj Høj and Søren Ryborg for organic synthesis assistance.

**Abbreviations**

cADPR, cyclic ADP ribose; NAADP, nicotinic acid adenine dinucleotide phosphate; AUC, area under the curve; bid, twice daily; DMEM, Dulbecco’s modified eagle medium; HRMS, high resolution mass spectrometry; IC$_{50}$, concentration of a test compound that produces half maximal inhibition; LC-MS, liquid chromatography - mass spectrometry; MTD, maximum tolerated dose; T$_{\text{max}}$, time of maximum drug concentration; C$_{\text{max}}$, maximum drug concentration; Vz, volume of distribution; CL, drug clearance; NMR, nuclear magnetic resonance; SAR, structure-activity relationship; SD, standard deviation

**References**


Casciaro, S.; Olcese, F.; Pierri, I.; Cagnetta, A.; Ferrando, F.; Ghio, R.; Gobbi, M.; Ballestrero, A.;

Dawson, K. M.; Dupuis, M; Duchosal, M. A. The NAD biosynthesis inhibitor APO866 has potent

Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) Inhibitors. J. Med.
Chem. 2013, 56 (16), 6279–6296.

29. Olesen, U. H.; Christensen, M. K.; Björkling, F.; Jäättelä, M.; Jensen, P. B.; Sehested, M.; Nielsen,
367(4), 799-804.

30. Watson, M.; Roulston, A.; Belec, L.; Billot, X.; Marcellus, R.; Bédard, D.; Bernier, C.; Branchaud,
Koch, E.; Lavoie, M.; Lawless, M.; Nguyen, M.; Paquette, D.; Turcotte, E.; Berger, A.; Mitchell,
M.; Shore, G.C.; Beauparlant, P. The Small Molecule GMX1778 Is a Potent Inhibitor of
NAD_Biosynthesis: rategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-

31. Khan, J.A.; Tao, X.; Tong, L. Molecular basis for the inhibition of human NMPRTase, a novel

toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis
    Karlsson, M. O.; Lonnebo, A.; Ahlgren, J. A phase I study of CHS 828 in patients with solid

34. Pishvaian, M.; Marshall, J.; Hwang, J.; Malik, S.; He, A.; Deeken, J.; Kelso, C.; Cotaria, I.; Berger,
    M. A. Phase I trial of GMX1777, an inhibitor of nicotinamide phosphoribosyl transferase
    (NAMPRT), given as a 24-hour infusion. J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-


    M.; Roulston, A.; Turcotte, E.; Watson, M. Preclinical development of the nicotinamide

    class of lipophilic quinazoline-based folic acid analogues: cytotoxic agents with a folate-

38. Orwig, K. S.; Dix, T. A. Synthesis of C-alpha methylated carboxylic acids: isosteres of arginine and
    lysine for use as N-terminal capping residues in polypeptides. Tetrahedron Lett. 2005, 46(41),
    7007-7009.

    Openers Targeted for Urge Urinary Incontinence. 1. N-Cyanogu anidine Bioisosteres Possessing in


59. Ditchfield, R.; Hehre, W. J.; Pople, J. A. Self-Consistent Molecular-Orbital Methods. IX. An
1971, 54, 724-728.
Table of Contents graphic

Biological Data: IC$_{50}$
0.025 nM in A2780
0.33 nM in MCF-7